Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × Crizotinib × Clear all

Phase

Phase 2 5 Phase 3 3 Phase 2/3 1 Phase 1/2 1

Status

Completed 4 Unknown 1 Recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 1 Lung Neoplasms 1

Interventions

Cyclophosphamide 33 Paclitaxel 27 Carboplatin 25 Gemcitabine 23 Nivolumab 22 Cisplatin 22 camrelizumab 20 Capecitabine 20 fludarabine 19 apatinib 18 Oxaliplatin 17 Immunotherapy, Adoptive 15 toripalimab 14 pembrolizumab 14 Radiotherapy 14 Rituximab 13 Drug Therapy 13 Bevacizumab 13 tislelizumab 12 Docetaxel 12 Temozolomide 11 Cetuximab 11 Injections 10 Dexamethasone 10 Cytarabine 10 anlotinib 9 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 9 Irinotecan 9 130-nm albumin-bound paclitaxel 9 Sorafenib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡